Biogen
Open
$200.24
Prev. Close
$200.23
High
$200.34
Low
$199.77
Market Snapshot
$29.36B
21.4
11.22
$9.68B
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 7,500 full-time employees. The firm is focused on discovering, developing, and delivering advanced therapies for people living with serious and complex diseases worldwide. The company operates a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). The company is focused on advancing its pipeline in neurology, specialized immunology, and rare diseases. Its marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of Friedreich's Ataxia; QALSODY for the treatment of ALS, and FUMADERM for the treatment of severe plaque psoriasis. The company also collaborations with Eisai on the commercialization of LEQEMBI for the treatment of Alzheimer's disease and Sage on the commercialization of ZURZUVAE for the treatment of Postpartum Depression (PPD).
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 7,500 full-time employees. The firm is focused on discovering, developing, and delivering advanced therapies for people living with serious and complex diseases worldwide. The company operates a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). The company is focused on advancing its pipeline in neurology, specialized immunology, and rare diseases. Its marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of Friedreich's Ataxia; QALSODY for the treatment of ALS, and FUMADERM for the treatment of severe plaque psoriasis. The company also collaborations with Eisai on the commercialization of LEQEMBI for the treatment of Alzheimer's disease and Sage on the commercialization of ZURZUVAE for the treatment of Postpartum Depression (PPD).
Recently from Cashu
Biogen Receives FDA Breakthrough Designation for SMA Treatment Salanersen
Biogen Inc. (Ticker: BIIB) has recently achieved a significant milestone by receiving the FDA Breakthrough Therapy Designation for salanersen, an investigational treatment designed for patients with s…
Biogen Faces FDA Delay for LEQEMBI in Alzheimer’s Treatment Amid Rising Investor Confidence
Biogen Inc (Ticker: BIIB) is navigating a pivotal moment in its quest to treat Alzheimer’s disease, as the U.S. Food and Drug Administration (FDA) has delayed its review of a key treatment. The compan…
Biogen's LEQEMBI Faces Extended FDA Review, New Action Date Set for August 2026
Biogen Inc. (Ticker: BIIB) is actively navigating the extended FDA review process for its Alzheimer’s treatment, LEQEMBI IQLIK, which could have significant implications for the company’s future in ne…
Biogen Acquires Felzartamab to Expand Immunology Portfolio in Greater China Market
Biogen's recent acquisition of felzartamab from TJ Biopharma marks a significant milestone in its strategic expansion within the immunology sector, particularly in the Greater China region. The deal,…